Focal Therapeutics Launches BioZorb LP, Expanding Utility of 3D Implant for Breast Cancer Patients

More Than 200 U.S. Centers Now Offer Bioabsorbable Marker Used in
Breast Conservation Therapy

ALISO VIEJO, Calif.–(BUSINESS WIRE)–#breastcancer–Focal Therapeutics, makers of the three-dimensional BioZorb™ implant
used in breast conservation therapy, announced it has launched BioZorb
LP™. The new “low-profile” design expands the spectrum of surgical sites
in which the bioabsorbable marker can be placed.

Compared to the original BioZorb spiral design, BioZorb LP accommodates
smaller surgical tissue sites. The marker has utility in smaller
breasts, in peripheral areas of the breast and in locations with less
surrounding tissue. Implantation of the marker after tumor removal helps
to delineate the surgical cavity for radiation treatment and long-term

“Everyone understands the need for delivering more personalized,
targeted and precise medical care,” said Alison Laidley, M.D., a Dallas
breast surgeon with Texas Breast Specialists who was among the first
physicians to use BioZorb LP. “These new designs allow me to offer the
BioZorb marker to more of my breast cancer patients.”

Breast conservation therapy (BCT) involves lumpectomy surgery to remove
breast cancer, typically followed by radiation to destroy any remaining
cancer cells. As with the spiral design, BioZorb LP is sutured into the
tumor bed at the time of cancer excision. The LP model maintains the
three dimensional aspects of the pioneering BioZorb spiral marker and
similarly contains 6 titanium clips held in a fixed array.

BioZorb serves as a communication tool between the surgeon and the
radiation oncologist. Clinicians report that the marker helps provide
more precise targeting of radiation treatment. It is also used to assist
with monitoring the area of surgery over time. There is no other
technology that marks the surgical site in this three dimensional

“Our radiation oncologists who oversee post-surgical radiation treatment
have embraced this technology,” Dr. Laidley said. “We have also seen
that patients support the idea of minimizing toxicity to surrounding
healthy tissues during their radiation treatment.”

The implant’s bioabsorbable material dissolves in the body over the
course of a year or more, while the marker clips remain in place.
Researchers have reported that after the device is implanted, the breast
tissue surrounds it and begins to heal. The device can be used during
oncoplastic surgery and reconstructive lumpectomy to help mark the
surgical site as the breast’s shape and contour is maintained.

The LP model is the latest product development from Focal Therapeutics.
Both the spiral and low profile BioZorb markers are available in a
variety of shapes and sizes.

BioZorb is now offered to patients at more than 200 U.S. cancer
treatment centers. The implant, which began commercialization less than
two years ago, has been used in more than 3,000 breast cancer surgeries.

About Focal Therapeutics

Focal Therapeutics pioneered the marking of soft-tissue surgical sites
in three dimensions. The company developed and manufactures BioZorb, a
proprietary, bioabsorbable device that provides 3D radiographic marking
and has unique clinical utility for patient imaging. Used by general,
breast and oncoplastic surgeons, the BioZorb line of products is now
offered to patients in leading academic and community cancer centers
throughout the U.S. For more information, call (U.S.) 949-600-5050, or


Dowling & Dennis Public Relations
Liz Dowling, 415-388-2794